NeuroSense Therapeutics LtdNRSN
Price$4.05

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$11.1MTTM through 31 Dec 2025
Free Cash Flow -$7.7MTTM through 31 Dec 2025

Margins

Current

Balance Sheet Health

Debt / Equity0.00x
Current Ratio0.31x
Net Debt-$166Knet cash position
Cash & Equivalents$166K

Quality Metrics

Altman Z-Score-99.53
Piotroski F-Score2 / 9

Multi-Year Trend

Diluted EPS-$0.44TTM
'22'23'24'25
FY2025: $-0.44

Dividend

No dividend

Capital Allocation

R&D Spend$6.2M

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.